Patients suffering burn injuries are particularly susceptible to infections.  Among the more troublesome infections are MRSA (Methicillin Resistant Staphylococcus Aureus). This is particularly true in patients hospitalized in institutions with a high institutional rate of MRSA. Hsiri Therapeutics is developing a novel topical treatment (HT-01) targeted against a variety of gram-positive organisms including MRSA and streptococcal species including, Vancomycin Resistant Enterococcus (VRE). Read More

While the clinical presentation of MRSA (Methicillin Resistant Staphylococcus Aureus) may be the same as any staph infection, treatment may be far more difficult. In its HT-02 discovery program, Hsiri Therapeutics is working on a variety of chemical leads for the systemic treatment of serious infections caused by MRSA and other gram-positive bacteria. Read More

Hsiri Therapeutics is developing new compounds that are highly active against both typical (Mycobacterium tuberculosis) and atypical strains (Mycobacterium Avium Complex or “MAC”) of mycobacteria. Infections from MAC are primarily lung diseases and they usually affect the elderly, people with previously damaged lungs and people who are immune compromised.Read More

HT-04 is a highly potent agent being developed for drug resistant Mycobacterium Tuberculosis.  Far from being a disease of the past, Tuberculosis, which infects approximately one of every three persons on earth, is a major world health problem.  No longer confined to the third world, Tuberculosis, including drug-resistant strains, threatens western countries as well.  Due to the emergence... Read More

HT-05 is a compound based on novel functional substitutions on the standard amino-penicillin frame.  The substitutions are remarkable in their ability to augment the activity of the base compound, particularly against Pseudomonas Aeruginosa... Read More

The need for novel antibiotics has been highlighted repeatedly as the ongoing evolution of antibiotic resistance periodically captures the public imagination.  Despite the emergence of one “superbug” after another, the major pharmaceutical companies have made relatively small efforts in the discovery of new antibiotics.

This job has largely fallen to small companies such as Hsiri Therapeutics.

>> Read More

HT-01

HT-01 is a novel topical compound being developed for both the treatment and the prophylaxis of gram-positive infections in susceptible patient populations.  HT-01 is highly active against most gram-positive infections, including Methicllin Resistant Staphlococcal Aureus (MRSA) and Vancomycin Resistant Enterococcus (VRE).   The compound is stable, easy to formulate, and has other attributes that make it an ideal topical treatment.

HT-02

HT-02 is the systemic drug that will be developed to treat serious gram-positive infections including MRSA and VRE.  It will be of the same chemical scaffold as HT-01.  There are currently several compounds being evaluated but there is no lead compound at this time.  However, we anticipate that within 12 months, a lead compound will be chosen and pre-clinical development will have begun.

HT-03

HT-03 is a highly potent anti-mycobacterial agent that is being developed to treat diseases caused by the Mycobacterium Avium-Intracellulare Complex (MAC).  These diseases are primarily pneumonias and currently have no satisfactory treatment regimen.  HT-03 is highly potent and has shown activity against this organism in-vitro, in tissue models, and in-vivo models.

HT-04

HT-04 is a highly potent agent being developed for drug resistant Mycobacterium Tuberculosis.  Far from being a disease of the past, Tuberculosis, which infects approximately one of every three persons on earth, is a major world health problem.  No longer confined to the third world, Tuberculosis, including drug-resistant strains, threatens western countries as well.  Due to the emergence of highly drug resistant strains of the disease, this could translate into a major public health concern anywhere.  HT-04 is the lead compound of a new class of agents that work by a mechanism of action different from the action of other drugs targeting TB.

HT-05

HT-05 is a compound based on novel functional substitutions on the standard amino-penicillin frame.  The substitutions are remarkable in their ability to augment the activity of the base compound, particularly against Pseudomonas Aeruginosa.  It is thought that the additional chemical substitutions on the compound are responsible for several new activities that may include, enhanced penetration of the drug into the bacterium, hindrance of bacterial beta-lactamase enzymes, and reduction of bacterium’s efflux pumping of the drug


Our Portfolio

Hsiri Therapeutics is currently engaged in the development of five compounds in important infectious disease areas. All of these disease areas represent a high unmet medical need. The Hsiri compounds are all that the preclinical stage at this time. All of the compounds have intellectual property protection for nearly the full twenty-year patent term.

Development Portfolio

Our Team

Hsiri Therapeutics, LLC was formed in early 2012. The Company’s primary focus is to develop new therapies for serious infectious diseases. Towards this end, the Company has several development assets that address important infectious diseases in both the developed and the developing world.

Our Team Page

Our Advisors

 Marvin Miller, Ph.D.

Marv is the George and Winifred Clark Professor of Chemistry and Biochemistry at the University of Notre Dame. His research has been involved in the discovery of antibiotics for the last thirty years. He is a consultant to a number of pharmaceutical companies on drug design and antibiotic discovery.

Christine Debouck, Ph.D.

Christine was a Senior Vice President of Proteomics at Glaxo Pharmaceuticals. Christine is currently a consultant for a number of pharmaceutical companies and was a previous reviewer for grants for the Gates Foundation.

Jeffrey Handler, Ph.D., M.B.A.
Jeff has held a variety of management positions at several pharmaceutical companies. Jeff has managed the toxicology studies of a number of INDs and has had particular expertise in the area of dermatologic agents.

Jeffrey Edelson, M.D.
Jeff has held a variety of management positions at several pharmaceutical companies.  He is trained as a pulmonary physician and is an expert in the treatment of both Mycobacterium Tuberculosis and Mycobacterium Avium Complex. Jeff was formerly in academia where he managed the Tuberculosis clinic at the University of Toronto.

Thais Sielecki, Ph.D.
Thais worked as Vice President, Preclinical Development of Cytokine PharmaSciences, Inc. prior to its successful sale to Ferring, and previously worked at DuPont-Merck, Bristol-Meyers Squibb and other pharmaceutical companies. She has a Ph.D. In medicinal chemistry from Colorado State University.

Latest Announcements

  • New Website Launch

    Hsiri Therapeutics,LLC, announced today the launch of its new website.